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Abstract
Background: Compared to static beam Intensity-Modulated Radiation Therapy (IMRT), the main advantage of
Volumetric Modulated Arc Therapy (VMAT) is a shortened delivery time, which leads to improved patient comfort
and possibly smaller intra-fraction movements. This study aims at a treatment planner-independent comparison of
radiotherapy treatment planning of IMRT and VMAT for head-and-neck cancer performed by several institutes and
based on the same CT- and contouring data.
Methods: Five institutes generated IMRT and VMAT plans for five oropharyngeal cancer patients using either
Pinnacle3 or Oncentra Masterplan to be delivered on Elekta linear accelerators.
Results: Comparison of VMAT and IMRT plans within the same patient and institute showed significantly better
sparing for almost all OARs with VMAT. The average mean dose to the parotid glands and oral cavity was reduced
from 27.2 Gy and 39.4 Gy for IMRT to 25.0 Gy and 36.7 Gy for VMAT, respectively. The dose conformity at 95% of
the prescribed dose for PTVboost and PTVtotal was 1.45 and 1.62 for IMRT and 1.37 and 1.50 for VMAT, respectively.
The average effective delivery time was reduced from 13:15 min for IMRT to 5:54 min for VMAT.
Conclusions: Independently of institution-specific optimization strategies, the quality of the VMAT plans including
double arcs was superior to step-and-shoot IMRT plans including 5–9 beam ports, while the effective treatment
delivery time was shortened by ~50% with VMAT.
Keywords: Head-and-neck cancer, Simultaneous integrated boost, Volumetric modulated arc therapy,
Intensity-modulated radiation therapy, Multi-institutional collaboration, SmartArc
Background
A notable difficulty with irradiation of head-and-neck can-
cer (HNC) is the large number of organs at risk (OARs) in
close proximity to regions with disease, including the sa-
livary glands, spinal cord and brainstem, larynx and
pharyngeal constrictors, oral mucosae, tongue and lips,
masseter as well as eyes and inner ears. The challenging
task for the treatment planner is to find the most optimal
trade-off in sparing the different OARs for each individual
patient. Often better sparing of one OAR implies sacri-
ficing another OAR, and in most patients high-grade ra-
diation-induced toxicity is unavoidable while ensuring
sufficient dose coverage of the planning target volume
(PTV). This may result in severe consequences for the
quality of life of these patients.
Introduction of intensity-modulated radiation therapy
(IMRT) techniques for the treatment of HNC replaced
conventional 3D-conformal radiation therapy (3D-CRT)
techniques, which resulted in much better dose con-
formity and sparing of the OARs and, therefore, less
radiation-induced toxicity [1-3]. When using IMRT for
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irradiation of oropharyngeal cancer salivary function was
less impaired, but the majority of the patients still suf-
fered from some degree of xerostomia [4-6]. Braam et al.
showed that the normal tissue complication probability
(NTCP) at several time points after radiation therapy was
less than 20% only if the mean dose to the parotid glands
was lower than 25 Gy [7], a dose level that even with
IMRT is often not achieved.
Recently, the next generation of IMRT techniques,
volumetric modulated arc therapy (VMAT) has become
widely available. Compared to static-beam IMRT, rota-
tional VMAT is supposed to decrease treatment delivery
times with at least similar or even better plan quality [8].
A number of single-institution studies have been published
for VMAT for HNC [9-15]. The authors of these studies
observed comparable or better PTV coverage and conform-
ity as well as better sparing of OARs for VMAT compared
to IMRT, while delivery times were shortened by 35-60%.
Recently, a multi-institutional study comparing different
treatment technologies planned in different institutes has
been reported [16]. However, no multi-institutional studies
comparing VMAT vs. IMRT planned by multiple institutes
using the same set of patients and treatment planning
engines have been reported so far.
The here presented study is the result of a collaboration
of five institutes in the Netherlands with similar equip-
ment. This collaboration aimed at a fast and safe clinical
introduction of VMAT for HNC (implemented under the
name SmartArc and Oncentra VMAT in the treatment
planning systems Pinnacle and Oncentra Masterplan,
respectively) on Elekta equipment and a high quality of
VMAT treatment planning in all participating institutes.
To evaluate the potential of VMAT all five participating
institutes generated IMRT and VMAT plans based on their
locally developed IMRT planning knowledge. The data
retrieved from this multi-institutional collaboration gives
the possibility of a treatment planner-independent com-
parison of VMAT vs. step-and-shoot IMRT for HNC. The
reason for this is that each institute uses different
optimization strategies and sets of objectives, and has dif-
ferent preferences for sparing OARs while identical patient
data was used for treatment planning.
Methods
Patient selection and contouring
For this retrospective treatment planning study, com-
puted tomography (CT) data including contouring of
five patients with oropharyngeal cancer were selected
(patient characteristics listed in Table 1). These patients
were previously treated with the standard clinical proto-
cols. According to the guidelines of the participating
institutes, the patient data was properly anonimized and
no informed consent of the patient was required. The
planning target volumes (PTVs) and organs at risk
(OARs), amongst others parotid glands, submandibular
glands, oral cavity, larynx, pharyngeal constrictors and
mandible, and if applicable, their corresponding sub-
structures, were delineated by an experienced clinician.
Delineation of an OAR was skipped in cases where the
PTV completely encompassed this (sub-) structure.
Dose prescription and plan acceptance parameters
Both VMAT and IMRT plans were generated for a treat-
ment in 32 fractions, to deliver a total dose of 56 Gy to the
PTVelective (i.e. a fraction dose of 1.75 Gy) and a simultan-
eous integrated boost (SIB) to 69.12 Gy to regions with
macroscopic disease (i.e. a fraction dose of 2.16 Gy).
Primary goal of treatment planning was to cover at least
99% of the volume of PTVelective and PTVboost with 95% of
the prescribed dose (53.2 Gy and 65.66 Gy, respectively),
and to restrict the volume receiving more than 107% in
the PTVboost of the prescribed dose (73.96 Gy) to a total
volume below 2 cm3 (all parameters summarized in
Table 2). The maximal allowed point dose to OARs was
54 Gy for the brainstem and 50 Gy for the spinal cord. In
addition, the mean dose preferably should be below 25 Gy
for the parotid glands (for at least one parotid), subman-
dibular glands and the oral cavity (if possible), and below
45 Gy for the larynx and pharyngeal constrictors.
Treatment planning
The CT data sets of five patients including contouring
were shared between the participating institutes (n = 5).
All institutes used their locally developed treatment
planning technique and inverse planning objectives
Table 1 Patient characteristics
Patient Location Classification Lymph
nodes
involved
PTVelective PTVboost
volume (cm3) volume (cm3)
1 Base of tongue R T1N2aM0 2 & 3 R 501 105
2 Tonsil R T2N2cM0 3 R & 2 bilat 621 234
3 Tonsil L T3N2cM0 1,2,3,4 bilat 992 381
4 Base of tongue R T3N2cM0 1b R & 2 bilat 836 422
5 Tonsil L T2N1M0 2 L 571 146
Average 704 258
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previously used with IMRT as starting point. VMAT and
IMRT plans were generated using Pinnacle3 v9.0 (Philips
Healthcare, Best, The Netherlands) (n = 4) or alterna-
tively Oncentra Masterplan (Nucletron, Veenendaal, The
Netherlands) (n = 1, institute C), which were commis-
sioned for treatment delivery using Elekta linear accel-
erators (Elekta Oncology, Crawley, United Kingdom)
equipped with either standard MLCs with 1 cm leaves
not allowing interdigitation (n = 4) or a beam modulator
with 0.4 cm leaves allowing interdigitation (n = 1, insti-
tute D).
Both treatment planning systems (TPSs) used in this
study employ nearly identical optimization modules deve-
loped by RaySearch Laboratories (RaySearch Laboratories,
Stockholm, Sweden) for VMAT planning: p-RayArc mar-
keted as SmartArc in Pinnacle3, and n-RayArc marketed
as Oncentra VMAT in Oncentra Masterplan; and for
IMRT planning: p-RayMachine marketed as Direct Ma-
chine Parameter Optimization (DMPO) in Pinnacle3, and
n-RayMachine marketed as Direct Step and Shoot (DSS)
in Oncentra Masterplan.
With VMAT and IMRT treatment planning, each
optimization is started with generation of fluence maps.
After typically 10–15 iterations, at the so-called conver-
sion iteration, segments are produced. Following an inter-
mediate collapsed-cone dose calculation, optimization is
continued using Direct Aperture Optimization (i.e.,
DMPO in Pinnacle3, and DSS in Oncentra Masterplan) up
to a total of 30–50 iterations.
IMRT planning parameters
Step-and-shoot IMRT plans were generated according to
each institute’s practice using typically 5–9 coplanar beams
(one institute used one additional non-coplanar beam at
330° at a couch angle of 90°) with a total of 50–70 seg-
ments. The lower limit for the segment size ranged from 4
to 9 cm2, with a minimum of 2 to 5 monitor units (MUs)
per segment.
VMAT planning parameters
VMAT plans were generated using one dual arc (i.e. a
double arc generated from a single arc at the segmen-
tation step) with an arc length close to 360°. Before start-
ing the study, all institutes had individually tested different
arc setups with, for example, only a single arc or one or
more dual arcs with varying arc lengths or combinations
thereof. During discussion of the first results within the
workgroup it was concluded that the use of a dual arc over
the full range would yield the most promising, clinically
acceptable results. The final resolution of control points
within the arc was set to 4°, which was found to allow suf-
ficient modulation at still acceptable duration of the
optimization. The collimator angle was typically set to a
value between 10° and 30° (or alternatively between 330°
and 350°) to avoid tongue-and-groove effects. All IMRT
and VMAT plans were generated using 6 MV photons.
VMAT plan optimization was restarted typically three to
five times after the initial run without prior resetting of the
earlier optimization result including segments and dose
rate along the arcs (so-called “warm re-starts”). At the end
of each of these optimization steps a full collapsed-cone
dose calculation is performed. After a restart of the
optimization altered dose distributions after adaptation of
segments are calculated as a small perturbation on the
previously calculated dose distribution using a simple
pencil-beam based approach. This approximation leads to
an accumulation of errors in the dose distribution during
the optimization process, which is then “repaired” by the
forced intermediate dose calculation after a fixed number
of iterations. This procedure greatly improves accordance
with the planning objectives in each step since dose distri-
bution after full dose calculation including inhomogeneity
corrections will be close to the altered dose distribution
found during the optimization process.
If necessary and desirable, target doses and/or objective
weights were adapted during the optimization process and
in-between re-starts to further lower dose to OARs and/or
improve PTV coverage. However, in case of large changes
in the objectives the optimization was repeated including
the segmentation step, i.e. re-started from scratch.
Planning objectives
Each institute started with their locally developed plan-
ning strategy including their specific set of objectives.
Table 2 Treatment planning objectives
Structure Parameter Objective Priority
PTVboost Prescribed
dose
69.12 Gy (32 * 2.16 Gy)
V99% > 95% of prescribed dose
(= 65.66 Gy)
High
D107% < 2 cm
3 High
PTVelective Prescribed
dose
56 Gy (32 * 1.75 Gy)
V99% > 95% of prescribed dose
(= 53.2 Gy)
High
Spinal Cord Dmax < 50 Gy High
Brainstem Dmax < 54 Gy High
Parotid glands Dmean Preferably < 25 Gy High-Medium
For at least the
contralateral gland
Submandibular
glands
Dmean Preferably < 25 Gy Medium
Oral cavity Dmean Preferably < 25 Gy Medium
Larynx Dmean Preferably < 45 Gy Medium-Low
Pharyngeal
constrictors
Dmean Preferably < 45 Gy Medium-Low
Other OARs Low
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After initial planning of one patient the planning proce-
dures and parameters were discussed in the group and as
a result, some institutes adjusted their individual planning
parameters and set of objectives. Hereafter, each institute
generated IMRT and VMAT plans for each of the five
patients (including the initially planned patient if neces-
sary) using a similar set of objectives for both IMRT and
VMAT, with only small or no changes to objective doses
and weights within the same patient.
A typical set of objectives to create a SIB plan always
included for both PTVelective and PTVboost minimum
and maximum dose objectives with high objective
weights, i.e. 50–100 (if 100 would be the maximum for
objective weights). In a limited number of institutes and
cases, also uniform dose objectives were added. Further-
more, all institutes included maximum point dose ob-
jectives for spinal cord and brain stem with mostly
intermediate objective weights, i.e. 5–50. Some institutes
expanded these structures by 3–5 mm to create an extra
safety margin, the so-called planning risk volume (PRV).
Dose to the other OARs including the left and right par-
otid, submandibular glands if delineated, oral cavity, lar-
ynx, pharyngeal constrictors and mandible was typically
steered using maximum EUD objectives with mostly low
objective weights, i.e. 1–10, and a gEUD factor of a = 1
(representing the mean dose). For each parotid, typically
for the part of the parotid outside the PTV (or the PTV
expanded by several mm) at least one dose volume histo-
gram (DVH) point objective was added with mostly low
objective weights, i.e. 1–10. In addition, all institutes used
ring structures to create steep dose gradients outside the
PTVelective and also between the two dose levels. Here,
mostly maximum point dose objectives with low to inter-
mediate objective weights, i.e. 1–20 were used. In
addition, some of the participating institutes used dose
objectives to restrict dose to one or more of the following
OARs: lung tops, shoulders, eyes and inner ears.
Determination of effective delivery times
Delivery times for IMRT and VMAT plans were deter-
mined on Elekta linear accelerators without making use of
the AFS (auto-field-setup) function to prepare beams and
segments for delivery. Tests with enabled AFS yielded a
time gain of 15 to 20 seconds per beam for IMRT, depen-
ding on the number of segments per beam; and for VMAT
a gain of ca. 20 seconds in-between the two arcs. There-
fore, if AFS is enabled the delivery times for IMRT
reported in this study would be reduced by 1:30 to
3:00 min. It should be noted, however, that our timings
neglect possible delays due to interaction with the patient
in-between the delivery.
Data retrieval and statistical analysis
For the purpose of comparison, all participating institutes
submitted their completed VMAT and IMRT plans in
DICOM RTdose format. The dose distributions were
imported into Pinnacle3 using an in-house developed im-
port script, if necessary normalized to the minimal
required PTV coverage, and DVHs and dose parameters
were retrieved for each plan using automated procedures.
The data from all five patients and five institutes was
pooled by treatment modality and analyzed in SPSS v15.0
as a whole and, in addition, stratified by patient and by
institute. Hypothesis testing was performed at 95%
Figure 1 Dose distributions in a transverse slice for IMRT and VMAT plans of all participating institutes. Dose distributions in a transverse
slice for IMRT and VMAT plans prepared by the participating institutes A to E. OARs are depicted with a thick solid line: oral cavity (brown),
parotid glands (orange) and spinal cord (blue).
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confidence level using a paired two-sided Wilcoxon
signed-rank test, if not otherwise specified.
Results
All institutes succeeded in producing clinically acceptable
VMAT and IMRT plans for SIB treatments of HNC for all
patients. All treatment planners aimed to limit dose to
OARs as much as possible and tightened the objectives
accordingly as long as the primary goals of the treatment
planning protocol were still fulfilled (see Table 2 for a pri-
ority listing). Only small differences were found between
IMRT plans from different institutes, which may be due
to each institute’s preferences and traditions in sparing the
different OARs in daily clinical practice. Similar observa-
tions were made for the VMAT plans from the different
institutes.
Dose distributions of IMRT and VMAT plans for a ty-
pical case prepared by the different institutes are shown in
Figure 1. Generally, regardless of patient and institute, with
VMAT the isodose surfaces encompassed the PTV tighter
with similar or better sparing of the OARs. This was re-
flected in steeper dose fall-offs for the corresponding
DVHs of the different PTVs (see Figure 2) and also smaller
dose conformity indices (CIs) for VMAT plans. The CI95,
defined by the ratio of total volume receiving 95% of the
prescribed doses (i.e., 53.2 Gy and 65.66 Gy for PTVelective
and PTVboost, respectively) and the volume of the PTV re-
ceiving the same dose, was found to be significantly better
with VMAT for both PTVboost and PTVtotal compared to
IMRT for the pooled data (summarized in Table 3); as well
when stratified by institute (see Table 4) or by patient (see
Table 5). Comparison of the DVHs of different OARs
reveals that with VMAT dose to OARs is in almost all
cases reduced compared to IMRT (see Figure 3).
In addition, with VMAT the isodose surfaces encom-
passed the PTVs more smoothly (i.e. less occurrence of
high dose bulges reaching far outside the PTVs) and fewer
hot spots outside the PTVs were observed (see Figure 1
for a typical example). This was also reflected in reduced
volumes of healthy tissue receiving doses above 30 Gy for
VMAT compared to IMRT. This is illustrated by the aver-
age absolute volume difference between both techniques
shown in Figure 4.
VMAT vs. IMRT based on pooled data
Comparison of the plan parameters for VMAT and
IMRT plans generated for the same patient by the same
institute showed significantly better sparing for most
OARs (see Table 3). Figure 4 shows averaged DVHs for
the pooled data for different OARs for VMAT (black
solid line) and IMRT (black dashed line) and correspon-
ding p-values (grey solid line). The average maximum
point dose and D1% (1% of the volume receives more than
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Figure 2 DVHs for the different PTVs for VMAT and IMRT and
p-values for pooled data. DVHs for PTVtotal, PTVboost and PTVelective
(= PTVtotal - PTVboost) for VMAT (solid line) and IMRT (dashed line).
DVHs are shown for pooled data of all institutes (black) and stratified
by institute (colors see legend). The p-values shown were obtained
for the pooled data using a paired two-sided Wilcoxon signed
rank test.
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this dose) to spinal cord and brain stem were lower with
VMAT, though only for the spinal cord at significant level.
With VMAT we observed a significantly lower average
mean dose and V39Gy (i.e. the percentage of volume recei-
ving more than 39 Gy) for ipsilateral and contralateral pa-
rotid glands, mandible, oral cavity and larynx. In addition,
the V25 Gy was significantly improved for the parotid
glands and the oral cavity. The contralateral submandibu-
lar gland was delineated in only three out of the five
patients and was always located in very close proximity to
the PTV. For this reason, we generally observed high
doses to the contralateral submandibular gland with both
Table 3 Plan parameters and significance of differences based on the pooled data of five patients and five institutes
VMAT
average ±
1 SD*
IMRT
average ±
1 SD*
Average difference ±
1 SD*
(VMAT – IMRT)
p-value
(Wilcoxon’s
signed-rank test)^
PTVboost CI95 1.37 ± 0.08 1.45 ± 0.11 -0.08 ± 0.09 .001
PTVtotal CI95 1.50 ± 0.09 1.62 ± 0.10 -0.12 ± 0.07 < .001
Normal tissue V5Gy (cm
3) 5050 ± 730 5030 ± 750 -20 ± 260 n.s.
V10Gy (cm
3) 4050 ± 630 3970 ± 590 -80 ± 160 n.s.
V20Gy (cm
3) 2830 ± 510 2860 ± 480 30 ± 150 n.s.
Spinal cord Dmax (Gy) 45.1 ± 3.5 46.6 ± 3.0 -1.5 ± 2.3 .001
D1% (Gy) 43.4 ± 3.7 44.4 ± 3.5 -0.9 ± 2.2 .005
Dmean (Gy) 29.3 ± 4.4 29.8 ± 3.6 -0.5 ± 2.4 n.s.
Brain stem Dmax (Gy) 46.4 ± 5.4 47.1 ± 4.7 -0.7 ± 4.6 n.s.
D1% (Gy) 43.8 ± 5.8 44.0 ± 5.5 -0.2 ± 4.9 n.s.
Dmean (Gy) 13.6 ± 3.6 14.5 ± 4.3 -1.0 ± 2.4 n.s.
Parotid gland ipsilateral V25Gy (%) 42.9 ± 15.6 50.3 ± 20.0 -7.4 ± 14.0 < .001
V39Gy (%) 30.0 ± 14.6 35.9 ± 18.6 -5.9 ± 11.2 < .001
Dmean (Gy) 28.0 ± 7.5 31.1 ± 9.1 -3.1 ± 5.1 < .001
Parotid gland contralateral V25Gy (%) 31.0 ± 7.1 34.5 ± 6.8 -3.5 ± 3.6 < .001
V39Gy (%) 18.3 ± 6.0 20.8 ± 6.1 -2.5 ± 2.5 < .001
Dmean (Gy) 22.0 ± 2.9 23.3 ± 2.8 -1.3 ± 1.5 < .001
Submandibular gland contralateral$ V39Gy (%) 88.1 ± 15.3 90.8 ± 13.5 -2.7 ± 6.9 n.s.
V60Gy (%) 16.4 ± 21.4 21.8 ± 27.3 -5.5 ± 8.5 .020
Dmean (Gy) 53.0 ± 5.9 54.2 ± 6.1 -1.3 ± 1.8 .027
Oral cavity V25Gy (%) 79.8 ± 22.9 86.3 ± 15.7 -6.5 ± 10.2 .011
V39Gy (%) 40.6 ± 22.0 48.8 ± 23.3 -8.2 ± 12.4 .002
Dmean (Gy) 36.7 ± 7.8 39.4 ± 7.3 -2.7 ± 2.8 < .001
Larynx V39Gy (%) 75.4 ± 24.7 79.1 ± 21.6 -3.8 ± 6.7 .012
V45Gy (%) 54.1 ± 27.4 58.2 ± 26.5 -4.1 ± 9.3 n.s.
Dmean (Gy) 45.5 ± 5.3 46.5 ± 4.4 -1.0 ± 1.5 .004
Pharyngeal constrictors° V39Gy (%) 78.7 ± 24.5 81.5 ± 20.0 -2.8 ± 15.2 n.s.
V45Gy (%) 59.7 ± 29.4 57.5 ± 25.5 2.2 ± 19.9 n.s.
Dmean (Gy) 47.1 ± 5.3 46.9 ± 3.8 0.2 ± 2.7 n.s.
Mandible° V39Gy (%) 74.0 ± 13.1 78.2 ± 11.8 -4.2 ± 8.4 .025
V60Gy (%) 25.7 ± 15.0 30.1 ± 16.2 -4.4 ± 5.1 < .001
Dmean (Gy) 48.6 ± 5.5 50.3 ± 5.7 -1.7 ± 1.7 < .001
Effective delivery time# (min:sec) 5:54 ± 1:05 13:15 ± 1:38 -7:21 ± 1:55 < .001
MUs – 643 ± 111 828 ± 149 -185 ± 129 < .001
* Standard deviations (SDs) are given as absolute values.
^ Hypothesis testing using a paired t-test results in almost identical significances at 95% confidence level.
$ The contralateral submandibular gland was delineated in only three patients.
° Not all institutes used objectives to control dose for these structures.
# Based on effective delivery times reported by four institutes.
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VMATand IMRT (see DVHs in Figure 3) and the plan ac-
ceptance parameters could not be fulfilled in any case.
VMAT delivery times estimated by the TPSs for both
arcs in the dual arc were on average 3:56 min and ranged
from 3:00 to 5:43 min, depending on each institute’s prac-
tice and difficulty of the case. In almost all cases, the TPS
made use of the maximum delivery time allocated by the
planner. The effective delivery times for VMAT (defined as
the time from start of the first arc and end of the second
arc) based on reports from four institutes were on average
5:54 min and ranged from 4:18 to 7:57 min. One institute
could not report effective delivery times for their VMAT
plans due to a delay with installing VMAT licenses for
their treatment machines. The delivery times of the IMRT
plans (defined from start of the first segment of the first
beam till end of the last segment of the last beam) were on
average 13:15 min and ranged from 9:40 to 15:56 min.
Based on these results, with VMAT for HNC the delivery
times can be expected to be reduced by ~50% compared
to IMRT.
Evaluation per institute
When stratifying the data by institute the overall picture
regarding improved plan parameters with VMAT
remained the same. For all plan parameters listed in
Table 4 with exception of the contralateral submandibular
gland, larynx and brain stem VMAT yielded better results,
regardless of institute, though not always at statistically
significant level. Please note that statistical power of the
stratified comparison is low since the statistical analysis is
based on only five pairs. However, the mean dose to the
ipsilateral parotid gland was in all cases significantly better
for VMAT, and for most institutes this also held for the
contralateral parotid gland.
The data listed in Table 4 also provides interesting in-
formation on each institute’s planning preferences. For in-
stitute C dose conformity to the PTVboost had probably a
relative high priority compared to other institutes, and
sparing of the ipsilateral parotid gland had lower priority,
as well as achieving low maximal doses to spinal cord
and brain stem. Institute A seemed to give high prefer-
ence to an as low as possible maximal point dose in
spinal cord and brain stem, whereas institutes B, D and E
probably tried to achieve a as low as possible mean dose
to the contralateral parotid gland, and institute D even
tried this for the ipsilateral parotid gland. Probably, insti-
tute D profitted here from using a beam modulator that
supports interdigitation of the MLC leaves, which allows
a higher degree of dose modulation.
Institute D also seemed to pay increased attention to
low doses to the oral cavity while dose conformity to the
PTVs seemed to play a less important role. These find-
ings were also supported by the underlying dosimetric
data of the individual patients, where almost all respect-
ive pairings of dosimetric parameters showed the same
preferences as the averages per institute listed in Table 4.
This supports our idea that even within quite defined
boundary conditions for treatment planning, including a
beforehand agreed treatment protocol and guidelines for
sparing OARs, quite some variation is possible in the
results of treatment planning studies like the one pre-
sented here.
Evaluation per patient
Likewise, stratification of the data by patient does not
largely change the previous findings. All plan parameters
except the mean doses to the larynx were lower for
VMAT compared to IMRT, though not all at significant
level (see Table 5). A reason for this observation could
be that the larynx is located in-between the two sides of
the PTVelective. With VMAT dose is delivered from many
Table 4 Plan parameters stratified by institute
Institute
Technique
A B C D E
PTVboost CI95 VMAT 1.39 1.35 1.31 1.43 1.38
IMRT 1.43 1.42 1.37 1.55 1.47
PTVtotal CI95 VMAT 1.51 1.49 1.54 1.45 1.51
IMRT 1.58 1.63 1.70 1.55 1.65
Spinal cord D1%
(Gy)
VMAT 39.1 45.6 47.7 41.1 43.8
IMRT 39.7 46.7 48.0 42.0 45.5
Brain stem D1%
(Gy)
VMAT 44.1 45.6 49.4 35.4 44.6
IMRT 42.9 45.8 46.9 40.0 44.4
Parotid gland
ipsilateral
Dmean
(Gy)
VMAT 27.6 26.6 33.3 23.2 29.3
IMRT 28.5 28.4 34.2 25.3 39.0
Parotid gland
contralateral
Dmean
(Gy)
VMAT 23.9 21.1 23.4 20.6 20.8
IMRT 24.8 22.7 23.6 21.5 23.6
Submandibular
gland
contralateral
Dmean
(Gy)
VMAT 49.4 58.0 57.4 47.5 52.6
IMRT 49.1 58.6 58.1 51.1 54.3
Oral cavity Dmean
(Gy)
VMAT 40.0 35.2 41.6 30.7 36.0
IMRT 42.5 40.2 43.6 33.5 37.4
Larynx Dmean
(Gy)
VMAT 51.4 44.5 49.4 43.5 38.6
IMRT 51.5 46.3 49.1 44.5 40.9
Pharyngeal
constrictors°
Dmean
(Gy)
VMAT 52.0 45.0 49.8 43.9 44.7
IMRT 49.0 45.7 48.8 44.2 46.6
Mandible° Dmean
(Gy)
VMAT 48.8 48.0 50.5 47.6 48.0
IMRT 49.7 49.9 51.1 49.3 51.3
Effective delivery
time
(min:
sec)
VMAT 4:51 6:50 – 5:15 6:41
IMRT 11:47 12:08 – 15:04 14:00
MUs – VMAT 600 602 540 774 698
IMRT 830 670 824 841 975
Pairs in bold denote statistically significant differences between VMAT
and IMRT.
Pairs in italic denote that the averaged plan parameter is better for IMRT.
° Not all institutes used objectives to control dose for these structures.
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directions and therefore more smeared out on OARs in
such constellations; whereas with IMRT large parts of
the dose are often given from directions omitting the
OARs in-between the PTV.
Discussion
Analysis of the data resulting from this multi-institutional
collaboration on the clinical introduction of VMAT for
HNC shows that VMAT plans including a double arc ge-
nerated with Pinnacle3 or Oncentra Masterplan have an
improved plan quality compared to IMRT plans with 5–9
beam ports. This observation is valid independently of
institution-specific planning strategies, choice of the set of
objectives, or preferences for sparing OARs. Based on the
effective delivery times reported from four institutes we
expect a reduction in the effective delivery times of ~50%
with VMAT compared to IMRT. The decreased treatment
delivery time obtained with VMAT will improve patient
comfort and result in a smaller impact of intra-fraction
movements, as described by Hoogeman et al. [17].
Several single-institution studies comparing VMAT and
IMRT for HNC have been reported in literature, most
based on RapidArc [9,10] and on SmartArc [11-15]. The
strength of the study presented here bases on its multi-
institutional setup and the rather limited regulations re-
garding the planning environment and procedures,
resulting in varying solutions for the same set of patients.
All plans were generated using planning environment and
procedures that were (or will shortly be) adopted for rou-
tine clinical use. As such, the data presented in this study
reflects a broad range of clinically achievable and accept-
able results and, therefore, allows a planner-independent
evaluation of the potential of VMAT vs. IMRT for irra-
diation of HNC.
Table 5 Plan parameters stratified by patient
Patient
Technique
1 2 3 4 5
PTVboost CI95 VMAT 1.37 ± 0.03 1.41 ± 0.06 1.46 ± 0.10 1.30 ± 0.03 1.31 ± 0.03
IMRT 1.54 ± 0.09 1.44 ± 0.04 1.50 ± 0.07 1.33 ± 0.05 1.42 ± 0.17
PTVtotal CI95 VMAT 1.43 ± 0.06 1.58 ± 0.07 1.52 ± 0.04 1.57 ± 0.08 1.40 ± 0.04
IMRT 1.53 ± 0.04 1.71 ± 0.09 1.63 ± 0.06 1.67 ± 0.10 1.57 ± 0.11
Spinal cord D1% (Gy) VMAT 42.1 ± 5.5 44.7 ± 2.6 43.4 ± 3.5 44.0 ± 4.1 42.9 ± 3.6
IMRT 43.8 ± 4.3 44.3 ± 2.9 44.8 ± 2.4 44.5 ± 4.7 44.4 ± 4.2
Brain stem D1% (Gy) VMAT 48.3 ± 4.7 42.1 ± 6.0 45.5 ± 5.6 41.4 ± 6.9 41.7 ± 5.0
IMRT 48.2 ± 1.9 45.7 ± 4.3 47.6 ± 4.2 40.5 ± 3.6 37.9 ± 5.0
Parotid gland ipsilateral Dmean (Gy) VMAT 21.7 ± 2.0 30.3 ± 4.9 24.8 ± 3.5 38.1 ± 9.2 25.1 ± 2.4
IMRT 23.6 ± 1.7 33.3 ± 3.5 30.5 ± 10.2 41.8 ± 11.0 26.3 ± 3.2
Parotid gland contralateral Dmean (Gy) VMAT 21.1 ± 1.9 23.1 ± 1.0 22.1 ± 2.1 25.0 ± 2.9 18.6 ± 1.9
IMRT 23.2 ± 1.9 24.1 ± 1.3 24.2 ± 0.5 25.3 ± 3.5 19.4 ± 1.5
Submandibular gland contralateral Dmean (Gy) VMAT 49.2 ± 6.0 55.0 ± 6.3 – – 54.8 ± 4.3
IMRT 49.6 ± 5.6 57.4 ± 6.4 – – 55.7 ± 3.7
Oral cavity Dmean (Gy) VMAT 31.3 ± 4.8 34.7 ± 5.4 33.3 ± 7.0 47.7 ± 1.7 36.5 ± 7.4
IMRT 34.2 ± 4.8 38.2 ± 3.1 37.4 ± 8.9 48.8 ± 1.7 38.7 ± 7.2
Larynx Dmean (Gy) VMAT 43.2 ± 4.4 44.9 ± 7.3 47.1 ± 4.6 46.8 ± 5.5 45.3 ± 5.5
IMRT 44.5 ± 4.3 45.5 ± 5.8 47.5 ± 4.2 47.7 ± 4.7 47.0 ± 3.9
Pharyngeal constrictors° Dmean (Gy) VMAT 42.3 ± 3.9 50.5 ± 6.6 48.9 ± 2.6 48.0 ± 4.9 45.7 ± 5.2
IMRT 42.1 ± 2.7 48.2 ± 3.7 49.3 ± 2.3 47.9 ± 3.6 46.9 ± 2.6
Mandible° Dmean (Gy) VMAT 41.7 ± 1.3 45.1 ± 1.4 55.2 ± 1.7 54.2 ± 1.5 46.7 ± 1.7
IMRT 42.4 ± 0.9 47.2 ± 1.2 57.6 ± 1.5 55.2 ± 1.6 48.9 ± 1.7
Effective delivery time (min:sec) VMAT 5:38 ± 0:42 6:00 ± 0:48 6:22 ± 1:28 6:07 ± 1:31 5:26 ± 1:04
IMRT 12:52 ± 0:41 13:09 ± 2:18 13:46 ± 1:07 13:30 ± 1:50 12:57 ± 2:23
MUs – VMAT 581 ± 55 641 ± 90 735 ± 170 668 ± 91 589 ± 73
IMRT 702 ± 92 836 ± 166 975 ± 125 855 ± 100 773 ± 142
Pairs in bold denote statistically significant differences between VMAT and IMRT.
Pairs in italic denote that the averaged plan parameter is better for IMRT.
° Not all institutes used objectives to control dose for these structures.
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IMRT has been the standard for radiation therapy of
advanced HNC in all participating institutes for several
years by now, and consequently, all institutes had a similar
level of experience in IMRT treatment planning when
starting this study. All participating institutes per-
formed IMRT and VMAT treatment planning using
the same CT data sets including contouring, ensuring
excellent comparability of the data between institutes.
The TPSs employed in this study, Pinnacle3 and
Oncentra, both make use of nearly identical VMAT
and IMRT optimization modules developed by Ray-
Search Laboratories. Therefore, the data retrieved
from these two TPSs was pooled and analyzed as one
population.
Pair-wise analysis of VMAT and IMRT plans within
the same patient and institute showed for almost all plan
pairs better sparing of OARs and dose conformity with
VMAT (please note that statistical power is low in the
stratified comparison). A major reason for this could be
the rotational character of VMAT which allows dose de-
livery from many more directions than with static-beam
IMRT with mostly 5–9 beam ports used. With VMAT
optimization dose is automatically redistributed along
the arc, which means that to a certain extent beam angle
optimization is inherent to VMAT. The additional
degrees of freedom with VMAT lead to the better dose
conformity, which in turn allows for a better sparing of
OARs in close proximity to the PTVs.
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Ipsilateral parotid gland 
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Contralateral parotid gland 
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Contralateral submandibular gland 
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Spinal cord
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Larynx 
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
10 20 30 40 50 60 70 80
0
0.2
0.4
0.6
0.8
1
p-
va
lu
e 
an
d 
no
rm
al
ize
d 
vo
lu
m
e 
Oral cavity 
dose [Gy]
VMAT all 
IMRT all 
p-value all 
institute A
institute B
institute C
institute D
institute E
Figure 3 DVHs for different OARs for VMAT and IMRT and p-value for pooled data. DVHs for parotid and submandibular glands, spinal
cord, larynx and oral cavity for VMAT (solid line) and IMRT (dashed line). DVHs are shown for pooled data of all institutes (black) and stratified by
institute (colors see legend). The p-values shown were obtained for the pooled data using a paired two-sided Wilcoxon signed rank test.
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Further exploration of the underlying dosimetric data
yielded that one institute chose to completely sacrifice one
of the parotid glands with IMRT for some patients, but
was able to spare it quite successfully with VMAT. Already
in 1996, Eisbruch et al. reported on a 3D-CRT technique
to spare the contralateral parotid gland, while deliberately
accepting underdosage in the surrounding target volume
with supposedly “lower” risk to contain disease [18]. With
the introduction of IMRT, this technique was refined and
the contralateral gland could be spared without hazarding
underdosage in the target volume; however, often at the
price of still sacrificing the ipsilateral gland [19]. It seems
that the paradigm “sacrificing one parotid gland to achieve
better sparing of the contralateral gland” often applied
with advanced HNC can be revisited with the advent of
VMAT.
From Table 4 we can see that some institutes have only
a few dosimetric parameters with significant statistical dif-
ference, whereas others have the majority of parameters
showing significant differences between VMAT and IMRT.
A reason for this may be that only limited efforts were
made to homogenize the IMRT techniques among ins-
titutes before starting the study. The dosimetric gain of
VMAT compared to each of the individual IMRT tech-
niques may therefore differ depending on how complex/
well-designed an IMRT technique of a specific institute
was compared to those of other institutes. Keeping these
“heterogeneous” sources in mind, the conclusions of the
presented study with VMAT leading to better dosimetric
results are even more striking.
Limitations of the here presented study include the small
sample size in the stratified comparisons, heterogeneity in
TPS and equipment of the participating institutes, and
limitation to a specific IMRT and VMAT implementation
combined with specific linear accelerator equipment. For
the comparisons stratified by institutes or patients the sam-
ple size of only five institutes and five patients is small,
resulting in a low statistical power in the stratified compari-
sons of VMAT and IMRT. However, the pooled data with
n = 25 allows drawing firm conclusions since for each
pairing we can assume statistical independency as different
treatment planners are involved. Regarding the heterogen-
eity of equipment, the two different TPSs employed in this
study may yield slightly different results for both IMRT and
VMAT plans, although the optimization modules in both
TPSs are of the same evolutionary origin. Regarding the
different MLCs used for treatment planning, the newer
generation beam modulator with narrower leaves of 4 mm
width also allowing interdigitation may lead to better dosi-
metric results for both IMRT and VMAT, especially regar-
ding dose conformity, due to increased degrees of freedom
in leave motion. However, any differences in boundary con-
ditions will be balanced since only pairs of IMRT and
VMAT plans achieved under the same conditions are com-
pared. The superior results for VMAT obtained in this
study may be valid only for the specific combination of
step-and-shoot IMRTand SmartArc/OncentraVMAT deli-
vered on Elekta linear accelerators equipped with the speci-
fied MLCs, and a similar comparison with sliding-window
IMRTcould lead to different results.
The data presented in this planning study comparing
VMAT and static-beam IMRT for HNC resulted from a
collaboration of five institutes in the Netherlands with
similar equipment, aiming at a safe and fast clinical intro-
duction of VMAT for HNC. Discussion of the planning
results and exchange of ideas and information regarding
VMAT treatment planning parameters and objectives be-
tween participating institutes during the collaboration
resulted in noticeable improvement of the VMAT plans.
We would like to stress that collaboration between insti-
tutes with similar equipment and treatment planning soft-
ware on the clinical introduction of a new treatment
modality can help to efficiently steepen the learning curve
and to achieve a high quality of treatment planning within
a short time. Problems and questions arising can be solved
during the discussions within the group, and as a result all
institutes require less time and effort for the clinical intro-
duction of the advanced treatment modality VMAT for
HNC.
Conclusions
VMAT plans including double arcs for simultaneous-
integrated boost treatments of head-and-neck cancer were
found to be improved compared to static-beam step-and-
shoot IMRT plans including 5–9 beam ports regarding
dose to OARs and dose conformity, while delivery times
were significantly shortened by 50%.
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Figure 4 Averaged absolute volume difference between DVHs
for healthy tissue and p-value for pooled data. Averaged
absolute volume difference between DVHs for IMRT and VMAT for
healthy tissue for the pooled data (black) and stratified by institute
(colors see legend). The p-values shown were obtained for the
pooled data using a paired two-sided Wilcoxon signed rank test.
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